BRNS vs. CMRX, ONCY, IFRX, SLS, YS, CUE, SPRO, ACRS, VTVT, and ANVS
Should you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Chimerix (CMRX), Oncolytics Biotech (ONCY), InflaRx (IFRX), SELLAS Life Sciences Group (SLS), YS Biopharma (YS), Cue Biopharma (CUE), Spero Therapeutics (SPRO), Aclaris Therapeutics (ACRS), vTv Therapeutics (VTVT), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical preparations" industry.
Chimerix (NASDAQ:CMRX) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk, community ranking and institutional ownership.
Barinthus Biotherapeutics has a net margin of 0.00% compared to Barinthus Biotherapeutics' net margin of -25,337.96%. Chimerix's return on equity of -36.61% beat Barinthus Biotherapeutics' return on equity.
Chimerix received 380 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 63.80% of users gave Chimerix an outperform vote.
45.4% of Chimerix shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 13.1% of Chimerix shares are owned by company insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Chimerix has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.45, suggesting that its share price is 145% less volatile than the S&P 500.
In the previous week, Chimerix and Chimerix both had 3 articles in the media. Chimerix's average media sentiment score of 1.44 beat Barinthus Biotherapeutics' score of 1.03 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media.
Chimerix currently has a consensus price target of $8.50, indicating a potential upside of 804.26%. Barinthus Biotherapeutics has a consensus price target of $8.00, indicating a potential upside of 253.98%. Given Barinthus Biotherapeutics' higher possible upside, equities research analysts plainly believe Chimerix is more favorable than Barinthus Biotherapeutics.
Barinthus Biotherapeutics has higher revenue and earnings than Chimerix. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.
Summary
Chimerix beats Barinthus Biotherapeutics on 8 of the 15 factors compared between the two stocks.
Get Barinthus Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Barinthus Biotherapeutics Competitors List
Related Companies and Tools
